Zeo ScientifiX Inc.
2.1800+0.21 (+10.7%)
Oct 29, 4:00:00 PM EDT · OTC Markets OTCQB · ZEOX · USD
Key Stats
Market Cap
14.28MP/E (TTM)
-Basic EPS (TTM)
-0.93Dividend Yield
0%Recent Filings
10-Q
Q3 FY2025 results
Zeo ScientifiX posted Q3 FY2025 revenues of $1.3M, up 19.7% y/y from $1.1M, driven by PPX™ service platform growth that offset softer allogenic biologics sales amid competition, while gross margins dipped to 82.5% from 83.9%. Operating losses widened to $2.1M from $1.2M, fueled by $3.9M in stock-based compensation within G&A expenses, leading to a net loss of $2.1M or $0.32 per diluted share on 6.4M shares—anti-dilutive effects excluded 4.3M potential shares. Cash fell to $314K after $335K YTD operating burn, with $698K in convertible notes due 2026 at 8% and $119K in finance leases through 2030; free cash flow not disclosed in the 10-Q. The BioLumina acquisition closed June 2025 for $200K (cash/stock/10% royalty up to $100K), adding $200K inventory and trademarks. FDA rules on biologics sales pose a key risk.
8-K
ZEO raises $1M privately
ZEO ScientifiX secured $1,000,000 from an accredited investor via a private placement of 250,000 common shares on July 25, 2025. The deal unfolds in ten equal monthly installments starting August 1, 2025, through May 1, 2026, under Section 4(a)(2) exemption. This infusion bolsters liquidity. Proceeds use not specified.
8-K
CSO resignation announced
ZEO ScientifiX announced the resignation of Dr. Peter A. M. Everts, Ph.D., as Chief Scientific and Technology Officer, effective August 1, 2025, following his departure on July 18. The filing provides no details on reasons or successor plans. This shift leaves a key scientific role vacant amid the company's tech-focused operations.
8-K
ZEO expands amid Florida stem law
ZEO ScientifiX launched an expansion on July 9, 2025, unveiling a redesigned website and partnerships with Plus4 Public Relations and Small Circle to capitalize on Florida's new SB-1768 law, effective July 1, 2025, authorizing compliant non-FDA-approved stem cell therapies for specific conditions. This positions ZEO's proprietary biologics platform, including Zofin and Patient Pure X, to lead the emerging regenerative medicine market amid expected demand surge. Yet risks loom from regulatory uncertainties and competition.
8-K
ZEO launches stem cell education
ZEO ScientifiX announced a physician-led Masterclass on June 24, 2025, to educate Florida doctors ahead of the SB-1768 law's July 1, 2025 effective date, which authorizes non-FDA-approved stem cell therapies in defined indications under strict compliance. This positions ZEO to supply compliant biologics like Zofin and PPX to specialties including pain management and orthopedics. The four-hour session covers legal, clinical, and ethical aspects. Forward-looking benefits hinge on regulatory adherence and market adoption.
IPO
Employees
Sector
Industry
AURX
Nuo Therapeutics, Inc.
2.29+0.00
CELU
Celularity Inc.
1.93-0.07
EXOZ
eXoZymes Inc.
12.65+0.29
KALA
KALA BIO, Inc.
0.80-0.03
KLTO
Klotho Neurosciences, Inc.
0.52-0.01
PHGE
BiomX Inc.
0.55-0.03
SEOVF
SERNOVA BIOTHERAPEUTICS INC.
0.12+0.00
ZBIO
Zenas BioPharma, Inc.
28.01-2.18
ZIVO
Zivo Bioscience, Inc.
16.99-0.01
ZVSA
ZyVersa Therapeutics, Inc.
0.14-0.01